



PRODUCT: **REYVOW®**

COMPANY: Eli Lilly and Company

**THERAPEUTIC AREA & INDICATION:**

A serotonin (5-HT) 1F receptor agonist indicated for the acute treatment of migraine with or without aura in adults

---

**ABOUT THE PRODUCT**

REYVOW is a 5-HT<sub>1F</sub> receptor agonist specifically designed to treat the underlying pathophysiology of migraine through a neurological mechanism of action. Innovations of REYVOW include:

- Highly specific agonist for the 5-HT<sub>1F</sub> receptor with >440-fold selectivity relative to other serotonin receptors, without vasoconstrictive properties.
- Demonstrated complete elimination of moderate to severe migraine pain and most bothersome symptoms of migraine attacks in population including patients with significant migraine disability and medical comorbidities.
- Provides clinical support for a revised understanding of migraine as a neurological rather than vascular disease.
- Offers a novel and effective option for patients with migraine.